Medical Science Liaison- West Coast

Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions.

In October 2025, Veradermics announced the closing of an oversubscribed $150 million Series C financing with top-tier healthcare investors. The financing will enable Veradermics to advance the development of our lead candidate, VDPHL01, as an oral, non-hormonal treatment for men and women with pattern hair loss (PHL). We are currently conducting three Phase 3 clinical trials as we work to deliver potentially transformative solutions and aspire to redefine the standard of care in dermatology. Learn more here .